Cargando…

Targeting MDM4 Splicing in Cancers

MDM4, an essential negative regulator of the P53 tumor suppressor, is frequently overexpressed in cancer cells that harbor a wild-type P53. By a mechanism based on alternative splicing, the MDM4 gene generates two mutually exclusive isoforms: MDM4-FL, which encodes the full-length MDM4 protein, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardot, Boris, Toledo, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333071/
https://www.ncbi.nlm.nih.gov/pubmed/28230750
http://dx.doi.org/10.3390/genes8020082
_version_ 1782511655511392256
author Bardot, Boris
Toledo, Franck
author_facet Bardot, Boris
Toledo, Franck
author_sort Bardot, Boris
collection PubMed
description MDM4, an essential negative regulator of the P53 tumor suppressor, is frequently overexpressed in cancer cells that harbor a wild-type P53. By a mechanism based on alternative splicing, the MDM4 gene generates two mutually exclusive isoforms: MDM4-FL, which encodes the full-length MDM4 protein, and a shorter splice variant called MDM4-S. Previous results suggested that the MDM4-S isoform could be an important driver of tumor development. In this short review, we discuss a recent set of data indicating that MDM4-S is more likely a passenger isoform during tumorigenesis and that targeting MDM4 splicing to prevent MDM4-FL protein expression appears as a promising strategy to reactivate p53 in cancer cells. The benefits and risks associated with this strategy are also discussed.
format Online
Article
Text
id pubmed-5333071
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53330712017-03-13 Targeting MDM4 Splicing in Cancers Bardot, Boris Toledo, Franck Genes (Basel) Review MDM4, an essential negative regulator of the P53 tumor suppressor, is frequently overexpressed in cancer cells that harbor a wild-type P53. By a mechanism based on alternative splicing, the MDM4 gene generates two mutually exclusive isoforms: MDM4-FL, which encodes the full-length MDM4 protein, and a shorter splice variant called MDM4-S. Previous results suggested that the MDM4-S isoform could be an important driver of tumor development. In this short review, we discuss a recent set of data indicating that MDM4-S is more likely a passenger isoform during tumorigenesis and that targeting MDM4 splicing to prevent MDM4-FL protein expression appears as a promising strategy to reactivate p53 in cancer cells. The benefits and risks associated with this strategy are also discussed. MDPI 2017-02-20 /pmc/articles/PMC5333071/ /pubmed/28230750 http://dx.doi.org/10.3390/genes8020082 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bardot, Boris
Toledo, Franck
Targeting MDM4 Splicing in Cancers
title Targeting MDM4 Splicing in Cancers
title_full Targeting MDM4 Splicing in Cancers
title_fullStr Targeting MDM4 Splicing in Cancers
title_full_unstemmed Targeting MDM4 Splicing in Cancers
title_short Targeting MDM4 Splicing in Cancers
title_sort targeting mdm4 splicing in cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333071/
https://www.ncbi.nlm.nih.gov/pubmed/28230750
http://dx.doi.org/10.3390/genes8020082
work_keys_str_mv AT bardotboris targetingmdm4splicingincancers
AT toledofranck targetingmdm4splicingincancers